Strain diversity plays no major role in the varying efficacy of rotavirus vaccines: An overview

Infection, Genetics and Evolution

Volumn 28, Issue , 2014, Pages 561-571

  Velasquez, Daniel E ^a   Parashar, Umesh D ^a   Jiang, Baoming ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Diarrhea; Efficacy; Genotypes; Rotavirus; Strains; Vaccines

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; RIX4414 VACCINE; VIRUS ANTIBODY;

ARTICLE; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION PREVENTION; INFECTIOUS DIARRHEA; MICROBIAL DIVERSITY; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ROTAVIRUS; ROTAVIRUS INFECTION; STRAIN DIFFERENCE; SYSTEMATIC REVIEW; VACCINATION; VALIDATION PROCESS; VIRAL GASTROENTERITIS; VIRUS STRAIN; BLOOD; GENETIC VARIATION; GENETICS; IMMUNOLOGY; META ANALYSIS; ROTAVIRUS INFECTIONS;

ROTAVIRUS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; GENETIC VARIATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED;

EID: 84912125155     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2014.10.008     Document Type: Article

References (96)

1. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., Binka F.N., Steele A.D., Laserson K.F., Ansah N.A., Levine M.M., Lewis K., Coia M.L., Attah-Poku M., Ojwando J., Rivers S.B., Victor J.C., Nyambane G., Hodgson A., Schodel F., Ciarlet M., Neuzil K.M. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:606-614.
2. Banyai K., Laszlo B., Duque J., Steele A.D., Nelson E.A., Gentsch J.R., Parashar U.D. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine 2012, 30(Suppl. 1):A122-130.
3. Bernstein D.I., Glass R.I., Rodgers G., Davidson B.L., Sack D.A. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. JAMA 1995, 273:1191-1196.
4. Bernstein D.I., Sack D.A., Rothstein E., Reisinger K., Smith V.E., O'Sullivan D., Spriggs D.R., Ward R.L. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 1999, 354:287-290.
5. Bernstein D.I., Sander D.S., Smith V.E., Schiff G.M., Ward R.L. Protection from rotavirus reinfection: 2-year prospective study. J. Infect. Dis. 1991, 164:277-283.
6. Bhandari N., Rongsen-Chandola T., Bavdekar A., John J., Antony K., Taneja S., Goyal N., Kawade A., Kang G., Rathore S.S., Juvekar S., Muliyil J., Arya A., Shaikh H., Abraham V., Vrati S., Proschan M., Kohberger R., Thiry G., Glass R., Greenberg H.B., Curlin G., Mohan K., Harshavardhan G.V., Prasad S., Rao T.S., Boslego J., Bhan M.K. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 2014.
7. Bhandari N., Sharma P., Glass R.I., Ray P., Greenberg H., Taneja S., Saksena M., Rao C.D., Gentsch J.R., Parashar U., Maldonado Y., Ward R.L., Bhan M.K. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine 2006, 24:5817-5823.
8. Bishop R.F., Barnes G.L., Cipriani E., Lund J.S. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. New Engl. J. Med. 1983, 309:72-76.
9. Breiman R.F., Zaman K., Armah G., Sow S.O., Anh D.D., Victor J.C., Hille D., Ciarlet M., Neuzil K.M. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine 2012, 30(Suppl. 1):A24-29.
10. Burns J.W., Siadat-Pajouh M., Krishnaney A.A., Greenberg H.B. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science (New York, N.Y.) 1996, 272:104-107.
11. Buttery J.P., Standish J., Bines J.E. Intussusception and rotavirus vaccines: consensus on benefits outweighing recognized risk. Pediatr. Infect. Dis. J. 2014, 33:772-773.
12. Carvalho-Costa F.A., Volotao Ede M., de Assis R.M., Fialho A.M., de Andrade Jda S., Rocha L.N., Tort L.F., da Silva M.F., Gomez M.M., de Souza P.M., Leite J.P. Laboratory-based rotavirus surveillance during the introduction of a vaccination program, Brazil, 2005-2009. Pediatr. Infect. Dis. J. 2011, 30:S35-41.
13. CDC-MMWR, 1999a. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. MMWR. Morbidity and mortality weekly report 48, 577-581.
14. CDC-MMWR, 1999b. Withdrawal of rotavirus vaccine recommendation. MMWR. Morbidity and mortality weekly report 48, 1007.
15. Chang W.C., Yen C., Wu F.T., Huang Y.C., Lin J.S., Huang F.C., Yu H.T., Chi C.L., Lin H.Y., Tate J.E., Parashar U.D., Wu H.S., Hsiung C.A. Effectiveness of 2 rotavirus vaccines against rotavirus disease in taiwanese infants. Pediatr. Infect. Dis. J. 2014, 33:e81-86.
16. Clark H.F., Bernstein D.I., Dennehy P.H., Offit P., Pichichero M., Treanor J., Ward R.L., Krah D.L., Shaw A., Dallas M.J., Laura D., Eiden J.J., Ivanoff N., Kaplan K.M., Heaton P. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J. Pediatr. 2004, 144:184-190.
17. Clark H.F., Burke C.J., Volkin D.B., Offit P., Ward R.L., Bresee J.S., Dennehy P., Gooch W.M., Malacaman E., Matson D., Walter E., Watson B., Krah D.L., Dallas M.J., Schodel F., Kaplan k.M., Heaton P. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr. Infect. Dis. J. 2003, 22:914-920.
18. Clark H.F., Lawley D., Shrager D., Jean-Guillaume D., Offit P.A., Whang S.Y., Eiden J.J., Bennett P.S., Kaplan K.M., Shaw A.R. Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: different dose response patterns to virus surface proteins VP7 and VP4. Pediatr. Infect. Dis. J. 2004, 23:206-211.
19. Clark H.F., Offit P.A., Ellis R.W., Eiden J.J., Krah D., Shaw A.R., Pichichero M., Treanor J.J., Borian F.E., Bell L.M., Plotkin S.A. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J. Infect. Dis. 1996, 174(Suppl. 1):S73-80.
20. Colomina J., Gil M.T., Codoner P., Buesa J. Viral proteins VP2, VP6, and NSP2 are strongly precipitated by serum and fecal antibodies from children with rotavirus symptomatic infection. J. Med. Virol. 1998, 56:58-65.
21. Correia J.B., Patel M.M., Nakagomi O., Montenegro F.M., Germano E.M., Correia N.B., Cuevas L.E., Parashar U.D., Cunliffe N.A., Nakagomi T. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J. Infect. Dis. 2010, 201:363-369.
22. Cortes J.E., Curns A.T., Tate J.E., Cortese M.M., Patel M.M., Zhou F., Parashar U.D. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. New Engl. J. Med. 2011, 365:1108-1117.
23. Cortese M.M., Immergluck L.C., Held M., Jain S., Chan T., Grizas A.P., Khizer S., Barrett C., Quaye O., Mijatovic-Rustempasic S., Gautam R., Bowen M.D., Moore J., Tate J.E., Parashar U.D., Vazquez M. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics 2013, 132:e25-33.
24. Danchin M., Kirkwood C.D., Lee K.J., Bishop R.F., Watts E., Justice F.A., Clifford V., Cowley D., Buttery J.P., Bines J.E. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. Vaccine 2013, 31:2610-2616.
25. Dang D.A., Nguyen V.T., Vu D.T., Nguyen T.H., Nguyen D.M., Yuhuan W., Baoming J., Nguyen D.H., Le T.L. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. Vaccine 2012, 30(Suppl. 1):A114-121.
26. de Palma O., Cruz L., Ramos H., de Baires A., Villatoro N., Pastor D., de Oliveira L.H., Kerin T., Bowen M., Gentsch J., Esposito D.H., Parashar U., Tate J., Patel M. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ (Clinical research ed.) 2010, 340:c2825.
27. Desselberger U. Genome rearrangements of rotaviruses. Adv. Virus Res. 1996, 46:69-95.
28. Fields B.N.K.D.M.H.P.M. Fields Virology 2007, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
29. Gastanaduy P.A., Sanchez-Uribe E., Esparza-Aguilar M., Desai R., Parashar U.D., Patel M., Richardson V. Effect of rotavirus vaccine on diarrhea mortality in different socioeconomic regions of Mexico. Pediatrics 2013, 131:e1115-1120.
30. Gladstone B.P., Ramani S., Mukhopadhya I., Muliyil J., Sarkar R., Rehman A.M., Jaffar S., Gomara M.I., Gray J.J., Brown D.W., Desselberger U., Crawford S.E., John J., Babji S., Estes M.K., Kang G. Protective effect of natural rotavirus infection in an Indian birth cohort. New Engl. J. Med. 2011, 365:337-346.
31. Glass R.I., Parashar U., Patel M., Gentsch J., Jiang B. Rotavirus vaccines: successes and challenges. J. Infect. 2014, 68(Suppl. 1):S9-18.
32. Gorrell R.J., Bishop R.F. Homotypic and heterotypic serum neutralizing antibody response to rotavirus proteins following natural primary infection and reinfection in children. J. Med. Virol. 1999, 57:204-211.
33. Gupta S., Ferguson N., Anderson R. Chaos, persistence, and evolution of strain structure in antigenically diverse infectious agents. Science (New York, N.Y.) 1998, 280:912-915.
34. Gurgel R.G., Bohland A.K., Vieira S.C., Oliveira D.M., Fontes P.B., Barros V.F., Ramos M.F., Dove W., Nakagomi T., Nakagomi O., Correia J.B., Cunliffe N., Cuevas L.E. Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program. Gastroenterology 2009, 137:1970-1975.
35. Gurgel R.Q., Correia J.B., Cuevas L.E. Effect of rotavirus vaccination on circulating virus strains. Lancet 2008, 371:301-302.
36. Gurgel R.Q., Cuevas L.E., Vieira S.C., Barros V.C., Fontes P.B., Salustino E.F., Nakagomi O., Nakagomi T., Dove W., Cunliffe N., Hart C.A. Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg. Infect. Dis. 2007, 13:1571-1573.
37. Heaton P.M., Goveia M.G., Miller J.M., Offit P., Clark H.F. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J. Infect. Dis. 2005, 192(Suppl. 1):S17-21.
38. Ichihara M.Y., Rodrigues L.C., Teles Santos C.A., Teixeira M.D., De Jesus S.R., Alvim De Matos S.M., Gagliardi Leite J.P., Barreto M.L. Effectiveness of rotavirus vaccine against hospitalized rotavirus diarrhea: a case-control study. Vaccine 2014.
39. Iturriza-Gomara M., Dallman T., Banyai K., Bottiger B., Buesa J., Diedrich S., Fiore L., Johansen K., Koopmans M., Korsun N., Koukou D., Kroneman A., Laszlo B., Lappalainen M., Maunula L., Marques A.M., Matthijnssens J., Midgley S., Mladenova Z., Nawaz S., Poljsak-Prijatelj M., Pothier P., Ruggeri F.M., Sanchez-Fauquier A., Steyer A., Sidaraviciute-Ivaskeviciene I., Syriopoulou V., Tran A.N., Usonis V., Van Ranst M., De Rougemont A., Gray J. Rotavirus genotypes co-circulating in Europe between 2006 and 2009 as determined by EuroRotaNet, a pan-European collaborative strain surveillance network. Epidemiol. Infect. 2011, 139:895-909.
40. Jiang B., Gentsch J.R., Glass R.I. The role of serum antibodies in the protection against rotavirus disease: an overview. Clin. Infect. Dis. 2002, 34:1351-1361.
41. Justino M.C., Linhares A.C., Lanzieri T.M., Miranda Y., Mascarenhas J.D., Abreu E., Guerra S.F., Oliveira A.S., da Silva V.B., Sanchez N., Meyer N., Shafi F., Ortega-Barria E., Soriano-Gabarro M., Colindres R.E. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belem, Brazil. Pediatr. Infect. Dis. J. 2011, 30:396-401.
42. Kawamura N., Tokoeda Y., Oshima M., Okahata H., Tsutsumi H., Van Doorn L.J., Muto H., Smolenov I., Suryakiran P.V., Han H.H. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine 2011, 29:6335-6341.
43. Kirkwood C.D. Genetic and antigenic diversity of human rotaviruses: potential impact on vaccination programs. J. Infect. Dis. 2010, 202(Suppl):S43-48.
44. Kirkwood C.D., Boniface K., Barnes G.L., Bishop R.F. Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix(R) and RotaTeq(R), into the National Immunization Program of Australia. Pediatr. Infect. Dis. J. 2011, 30:S48-53.
45. Kirkwood, C.D., Roczo, S., Boniface, K., Bishop, R.F., Barnes, G.L., 2011b. Australian Rotavirus Surveillance Program annual report, 2010/11. Communicable diseases intelligence quarterly report 35, 281-287.
46. Li R.C., Huang T., Li Y., Luo D., Tao J., Fu B., Si G., Nong Y., Mo Z., Liao X., Luan I., Tang H., Rathi N., Karkada N., Han H.H. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Hum. Vaccin. Immunother. 2014, 10:11-18.
47. Linhares A.C., Gabbay Y.B., Mascarenhas J.D., de Freitas R.B., Oliveira C.S., Bellesi N., Monteiro T.A., Lins-Lainson Z., Ramos F.L., Valente S.A. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull. World Health Organ. 1996, 74:491-500.
48. Linhares A.C., Velazquez F.R., Perez-Schael I., Saez-Llorens X., Abate H., Espinoza F., Lopez P., Macias-Parra M., Ortega-Barria E., Rivera-Medina D.M., Rivera L., Pavia-Ruz N., Nunez E., Damaso S., Ruiz-Palacios G.M., De Vos B., O'Ryan M., Gillard P., Bouckenooghe A. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371:1181-1189.
49. Liu L., Johnson H.L., Cousens S., Perin J., Scott S., Lawn J.E., Rudan I., Campbell H., Cibulskis R., Li M., Mathers C., Black R.E. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012, 379:2151-2161.
50. Martcheva M., Bolker B.M., Holt R.D. Vaccine-induced pathogen strain replacement: what are the mechanisms?. J. R. Soc. Interface 2008, 5:3-13.
51. Mascarenhas J.D., Leite J.P., Gabbay Y.B., Almeida M.L., Linhares A.C. Tetravalent rhesus-human rotavirus vaccine (RRV-TV) in Belem, Brazil: efficacy against prevailing P and G genotypes. J. Trop. Pediatr. 2002, 48:300-302.
52. Mast T.C., Khawaja S., Espinoza F., Paniagua M., Del Carmen L.P., Cardellino A., Sanchez E. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. Pediatr. Infect. Dis. J. 2011, 30:e209-215.
53. Matthijnssens J., Bilcke J., Ciarlet M., Martella V., Banyai K., Rahman M., Zeller M., Beutels P., Van Damme P., Van Ranst M. Rotavirus disease and vaccination: impact on genotype diversity. Future Microbiol. 2009, 4:1303-1316.
54. Matthijnssens J., Ciarlet M., Heiman E., Arijs I., Delbeke T., McDonald S.M., Palombo E.A., Iturriza-Gomara M., Maes P., Patton J.T., Rahman M., Van Ranst M. Full genome-based classification of rotaviruses reveals a common origin between human Wa-Like and porcine rotavirus strains and human DS-1-like and bovine rotavirus strains. J. Virol. 2008, 82:3204-3219.
55. Matthijnssens J., Nakagomi O., Kirkwood C.D., Ciarlet M., Desselberger U., Van Ranst M. Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes?. Expert Rev. Vaccines 2012, 11:1347-1354.
56. Matthijnssens J., Van Ranst M. Genotype constellation and evolution of group A rotaviruses infecting humans. Curr. Opin. Virol. 2012, 2:426-433.
57. Matthijnssens J., Zeller M., Heylen E., De Coster S., Vercauteren J., Braeckman T., Van Herck K., Meyer N., Pircon J.Y., Soriano-Gabarro M., Azou M., Capiau H., De Koster J., Maernoudt A.S., Raes M., Verdonck L., Verghote M., Vergison A., Van Damme P., Van Ranst M. Higher proportion of G2P[4] rotaviruses in vaccinated hospitalised cases compared to unvaccinated hospitalised cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses. Clin. Microbiol. Infect. 2014.
58. Moulton L.H., Staat M.A., Santosham M., Ward R.L. The protective effectiveness of natural rotavirus infection in an American Indian population. J. Infect. Dis. 1998, 178:1562-1566.
59. Nakagomi T., Cuevas L.E., Gurgel R.G., Elrokhsi S.H., Belkhir Y.A., Abugalia M., Dove W., Montenegro F.M., Correia J.B., Nakagomi O., Cunliffe N.A., Hart C.A. Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine. Arch. Virol. 2008, 153:591-593.
60. O'Ryan M. The ever-changing landscape of rotavirus serotypes. Pediatr. Infect. Dis. J. 2009, 28:S60-62.
61. O'Ryan M.L., Matson D.O., Estes M.K., Bartlett A.V., Pickering L.K. Molecular epidemiology of rotavirus in children attending day care centers in Houston. J. Infect. Dis. 1990, 162:810-816.
62. Patel M., Pedreira C., De Oliveira L.H., Tate J., Orozco M., Mercado J., Gonzalez A., Malespin O., Amador J.J., Umana J., Balmaseda A., Perez M.C., Gentsch J., Kerin T., Hull J., Mijatovic S., Andrus J., Parashar U. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009, 301:2243-2251.
63. Patel M.M., Patzi M., Pastor D., Nina A., Roca Y., Alvarez L., Iniguez V., Rivera R., Tam K.I., Quaye O., Bowen M., Parashar U., De Oliveira L.H. Effectiveness of monovalent rotavirus vaccine in Bolivia: case-control study. BMJ (Clinical research ed.) 2013, 346:f3726.
64. PATH, 2014. Rotavirus vaccine access and delivery. <> (accessed 20.09.2014). http://sites.path.org/rotavirusvaccine/country-introduction-maps-and-spreadsheet/.
65. Payne D.C., Boom J.A., Staat M.A., Edwards K.M., Szilagyi P.G., Klein E.J., Selvarangan R., Azimi P.H., Harrison C., Moffatt M., Johnston S.H., Sahni L.C., Baker C.J., Rench M.A., Donauer S., McNeal M., Chappell J., Weinberg G.A., Tasslimi A., Tate J.E., Wikswo M., Curns A.T., Sulemana I., Mijatovic-Rustempasic S., Esona M.D., Bowen M.D., Gentsch J.R., Parashar U.D. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin. Infect. Dis. 2013, 57:13-20.
66. Perez-Schael I., Guntinas M.J., Perez M., Pagone V., Rojas A.M., Gonzalez R., Cunto W., Hoshino Y., Kapikian A.Z. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. New Engl. J. Med. 1997, 337:1181-1187.
67. Phua K.B., Lim F.S., Lau Y.L., Nelson E.A., Huang L.M., Quak S.H., Lee B.W., Teoh Y.L., Tang H., Boudville I., Oostvogels L.C., Suryakiran P.V., Smolenov I.V., Han H.H., Bock H.L. Safety and efficacy of human rotavirus vaccine during the first 2years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009, 27:5936-5941.
68. Pitzer V.E., Patel M.M., Lopman B.A., Viboud C., Parashar U.D., Grenfell B.T. Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:19353-19358.
69. Ray P., Malik J., Singh R.K., Bhatnagar S., Bahl R., Kumar R., Bhan M.K. Rotavirus nonstructural protein NSP4 induces heterotypic antibody responses during natural infection in children. J. Infect. Dis. 2003, 187:1786-1793.
70. Rennels M.B., Glass R.I., Dennehy P.H., Bernstein D.I., Pichichero M.E., Zito E.T., Mack M.E., Davidson B.L., Kapikian A.Z. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines-report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996, 97:7-13.
71. Reves R.R., Hossain M.M., Midthun K., Kapikian A.Z., Naguib T., Zaki A.M., DuPont H.L. An observational study of naturally acquired immunity to rotaviral diarrhea in a cohort of 363 Egyptian children. Calculation of risk for second episodes using age-specific person-years of observation. Am. J. Epidemiol. 1989, 130:981-988.
72. Richardson S.C., Grimwood K., Bishop R.F. Analysis of homotypic and heterotypic serum immune responses to rotavirus proteins following primary rotavirus infection by using the radioimmunoprecipitation technique. J. Clin. Microbiol. 1993, 31:377-385.
73. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., Cheuvart B., Espinoza F., Gillard P., Innis B.L., Cervantes Y., Linhares A.C., Lopez P., Macias-Parra M., Ortega-Barria E., Richardson V., Rivera-Medina D.M., Rivera L., Salinas B., Pavia-Ruz N., Salmeron J., Ruttimann R., Tinoco J.C., Rubio P., Nunez E., Guerrero M.L., Yarzabal J.P., Damaso S., Tornieporth N., Saez-Llorens X., Vergara R.F., Vesikari T., Bouckenooghe A., Clemens R., De Vos B., O'Ryan M. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New Engl. J. Med. 2006, 354:11-22.
74. Salinas B., Perez Schael I., Linhares A.C., Ruiz Palacios G.M., Guerrero M.L., Yarzabal J.P., Cervantes Y., Costa Clemens S., Damaso S., Hardt K., De Vos B. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr. Infect. Dis. J. 2005, 24:807-816.
75. Santosham M., Moulton L.H., Reid R., Croll J., Weatherholt R., Ward R., Forro J., Zito E., Mack M., Brenneman G., Davidson B.L. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J. Pediatr. 1997, 131:632-638.
76. Snelling T.L., Andrews R.M., Kirkwood C.D., Culvenor S., Carapetis J.R. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin. Infect. Dis. 2011, 52:191-199.
77. Snelling T.L., Schultz R., Graham J., Roseby R., Barnes G.L., Andrews R.M., Carapetis J.R. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin. Infect. Dis. 2009, 49:428-431.
78. Staat M.A., Payne D.C., Donauer S., Weinberg G.A., Edwards K.M., Szilagyi P.G., Griffin M.R., Hall C.B., Curns A.T., Gentsch J.R., Salisbury S., Fairbrother G., Parashar U.D. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics 2011, 128:e267-275.
79. Steele A.D., Neuzil K.M., Cunliffe N.A., Madhi S.A., Bos P., Ngwira B., Witte D., Todd S., Louw C., Kirsten M., Aspinall S., Van Doorn L.J., Bouckenooghe A., Suryakiran P.V., Han H.H. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infect. Dis. 2012, 12:213.
80. The World Bank, 2014. Country and lending groups. <> (accessed 20.09.2014). http://data.worldbank.org/country.
81. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet. Infect. Dis. 2012, 12:136-141.
82. Treanor J.J., Clark H.F., Pichichero M., Christy C., Gouvea V., Shrager D., Palazzo S., Offit P. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatr. Infect. Dis. J. 1995, 14:301-307.
83. Tregnaghi M.W., Abate H.J., Valencia A., Lopez P., Da Silveira T.R., Rivera L., Rivera Medina D.M., Saez-Llorens X., Gonzalez Ayala S.E., De Leon T., Van Doorn L.J., Pilar Rubio M.D., Suryakiran P.V., Casellas J.M., Ortega-Barria E., Smolenov I.V., Han H.H. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr. Infect. Dis. J. 2011, 30:e103-108.
84. VanCott J.L., Prada A.E., McNeal M.M., Stone S.C., Basu M., Huffer B., Smiley K.L., Shao M., Bean J.A., Clements J.D., Choi A.H., Ward R.L. Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates. J. Virol. 2006, 80:4949-4961.
85. Velazquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., Glass R.I., Estes M.K., Pickering L.K., Ruiz-Palacios G.M. Rotavirus infections in infants as protection against subsequent infections. N. Engl. J. Med. 1996, 335:1022-1028.
86. Vesikari T., Clark H.F., Offit P.A., Dallas M.J., DiStefano D.J., Goveia M.G., Ward R.L., Schodel F., Karvonen A., Drummond J.E., DiNubile M.J., Heaton P.M. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006, 24:4821-4829.
87. Vesikari T., Karvonen A., Ferrante S.A., Kuter B.J., Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1years following the last dose of vaccine. Pediatr. Infect. Dis. J. 2010, 29:957-963.
88. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., Meurice F., Han H.H., Damaso S., Bouckenooghe A. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
89. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., Dallas M.J., Heyse J.F., Goveia M.G., Black S.B., Shinefield H.R., Christie C.D., Ylitalo S., Itzler R.F., Coia M.L., Onorato M.T., Adeyi B.A., Marshall G.S., Gothefors L., Campens D., Karvonen A., Watt J.P., O'Brien K.L., DiNubile M.J., Clark H.F., Boslego J.W., Offit P.A., Heaton P.M. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New Engl. J. Med. 2006, 354:23-33.
90. Ward R.L., Bernstein D.I., Smith V.E., Sander D.S., Shaw A., Eiden J.J., Heaton P., Offit P.A., Clark H.F. Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. J. Infect. Dis. 2004, 189:2290-2293.
91. Ward R.L., Clark H.F., Offit P.A. Influence of potential protective mechanisms on the development of live rotavirus vaccines. J. Infect. Dis. 2010, 202(Suppl. S72-79).
92. Ward R.L., McNeal M.M., Sander D.S., Greenberg H.B., Bernstein D.I. Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children. J. Virol. 1993, 67:464-468.
93. Yen C., Figueroa J.R., Uribe E.S., Carmen-Hernandez L.D., Tate J.E., Parashar U.D., Patel M.M., Richardson Lopez-Collado V. Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in Mexico. J. Infect. Dis. 2011, 204:783-786.
94. Yuan L., Ishida S., Honma S., Patton J.T., Hodgins D.C., Kapikian A.Z., Hoshino Y. Homotypic and heterotypic serum isotype-specific antibody responses to rotavirus nonstructural protein 4 and viral protein (VP) 4, VP6, and VP7 in infants who received selected live oral rotavirus vaccines. J. Infect. Dis. 2004, 189:1833-1845.
95. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., Podder G., Vu D.T., Le T.P., Luby S.P., Le H.T., Coia M.L., Lewis K., Rivers S.B., Sack D.A., Schodel F., Steele A.D., Neuzil K.M., Ciarlet M. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623.
96. Zeller M., Rahman M., Heylen E., De Coster S., De Vos S., Arijs I., Novo L., Verstappen N., Van Ranst M., Matthijnssens J. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010, 28:7507-7513.